
QuidelOrtho Corporation
NASDAQ•QDEL
CEO: Mr. Joseph M. Busky CPA
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1991-02-01
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Contact Information
Market Cap
$1.89B
P/E (TTM)
-1.6
79.7
Dividend Yield
--
52W High
$49.45
52W Low
$19.50
52W Range
Rank44Top 40.4%
4.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$699.90M-3.74%
4-Quarter Trend
EPS
-$10.78+3493.33%
4-Quarter Trend
FCF
-$94.70M-232.63%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Net Loss Significantly Narrows Nine month net loss reduced to $(1,001.1)M$ from $(1,873.6)M$ previous period, reflecting lower charges recognized.
Goodwill Impairment Declines Goodwill impairment charge dropped to $700.7M$ for nine months, compared to $1.74B$ recognized last year.
Core Labs Revenue Rises Labs segment revenue increased 5% to $1,116.5M$ for nine months, driven by reagents and consumables growth.
Working Capital Improves Working capital reached $598.8M$ as of September 28, 2025, significantly increasing from $220.1M$ year-end.
Risk Factors
Total Revenue Decreases Nine month total revenues fell 3% to $2,006.6M$, impacted by respiratory product variability and pricing pressures.
Donor Screening Portfolio Exits Donor Screening revenue fell 57% to $40.8M$ (9M) due to planned wind-down of U.S. portfolio operations.
Operating Cash Flow Negative Net cash used for operating activities totaled $(26.7)M$ for nine months, contrasting prior period cash generation.
Increased Restructuring Costs Restructuring and integration charges rose to $234.6M$ (9M) due to Optimization Plan and Savanna Exit costs.
Outlook
Optimization Plan Cost Savings Optimization Plan targets $50M$ net cost savings by 2027 through facility rationalization and procurement efforts.
Strategic Focus Shifts Company refocusing Molecular Diagnostics, planning Savanna Exit completion by H1 2027, intending to acquire LEX Diagnostics.
Short-Term Liquidity Secure Cash and Revolving Credit Facility sufficient to fund near-term capital and operating needs for at least 12 months.
Growing Reagent Rentals Increasing reagent rental placements to lower customer upfront costs, growing installed base and recurring revenue streams.
Peer Comparison
Revenue (TTM)
QDEL$2.72B
TLRY$1.16B
NVCR$642.27M
Gross Margin (Latest Quarter)
VRDN100.0%
CLDX100.0%
QDEL93.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| RCUS | $2.73B | -7.7 | -69.8% | 10.1% |
| VRDN | $2.64B | -7.7 | -55.1% | 3.7% |
| CLDX | $1.97B | -9.8 | -27.6% | 0.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.4%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention
Research & Insights
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 28, 2025|Filed: Nov 6, 2025|Revenue: $699.90M-3.7%|EPS: $-10.78+3493.3%MissForm 10-Q - Q2 2025
Period End: Jun 29, 2025|Filed: Aug 6, 2025|Revenue: $615.10M-3.3%|EPS: $-3.77+71.4%MissForm 10-Q - Q1 2025
Period End: Mar 30, 2025|Filed: May 8, 2025|Revenue: $692.80M-2.4%|EPS: $-0.19-99.3%MissForm 10-K - FY 2024
Period End: Dec 29, 2024|Filed: Feb 27, 2025|Revenue: $2.78B-7.2%|EPS: $-30.54-20260.0%MissForm 10-Q - Q3 2024
Period End: Sep 29, 2024|Filed: Nov 8, 2024|Revenue: $727.10M-2.3%|EPS: $-0.30+57.9%MissForm 10-K/A - FY 2023
Period End: Dec 31, 2023|Filed: Aug 1, 2024|Revenue: $3.00B-8.2%|EPS: $-0.15-101.6%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 1, 2024|Revenue: $636.30M-4.3%|EPS: $-2.20+175.0%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 9, 2024|Revenue: $709.70M-16.1%|EPS: $-25.50-3593.2%Miss